Tardive dyskinesia shares features with other movement disorders, such as Tourette syndrome and drug-induced Parkinsonism. But a diagnostic evaluation can reveal which condition is causing the ...

In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by dopamine-blocking medications. Below are some of the highlights of the year.

Nycole was compensated by Neurocrine Biosciences, Inc. to share her story. As a result of being on those medications, Nycole developed tardive dyskinesia (TD), a condition that affects approximately ...

Tardive dyskinesia is a drug-induced neurological disorder characterized by involuntary movements of the face and body. The condition develops as a side effect of long-term use of antipsychotics and ...

Tardive dyskinesia is a hyperkinetic movement disorder that causes faces to move involuntarily and abnormally. It is considered to be a drug-induced movement disorder. Movements often occur in the ...

Whether someone you know already has tardive dyskinesia (TD) or they're at risk for it because of a medicine they take, you might wonder how you can help. People who have this movement disorder need a ...

Christoph U. Correll, MD, professor of psychiatry at The Zucker School of Medicine at Hofstra/Northwell and professor and chair of the department of child and adolescent psychiatry at Charité ...

—According to new research, oral vertical dyskinesia (OVD), also known by the older term “rabbit syndrome,” may be part of a spectrum of symptoms of drug-induced parkinsonism and tardive dyskinesia, ...

The gold standard is the Abnormal Involuntary Movement Scale, or the AIMS, although generally we kind of want to avoid premature TD labels, and we want to ensure that there's a causal link, in this ...

Tardive dyskinesia is a medication-induced movement disorder. It's typically caused by certain classes of medicines that block dopamine receptors in the brain. The typical offenders are a class of ...

TEL AVIV, Israel, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that a new analysis from the European cohort of the RIM-TD open-label ...